Detalhe da pesquisa
1.
Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group.
Pediatr Blood Cancer
; : e31009, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627882
2.
Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Pediatr Blood Cancer
; 71(4): e30847, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38282125
3.
Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: A report from Children's Oncology Group.
Pediatr Blood Cancer
; : e30436, 2023 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243336
4.
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.
Pediatr Blood Cancer
; 69(6): e29644, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35253352
5.
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
Pediatr Blood Cancer
; 67(10): e28606, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32706456
6.
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Pediatr Blood Cancer
; 67(6): e28222, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32207565
7.
Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
Pediatr Blood Cancer
; 66(11): e27952, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31397065
8.
Alveolar soft part sarcoma in children and young adults: A report of 69 cases.
Pediatr Blood Cancer
; 65(5): e26953, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29350467
9.
Two cases of humoral hypercalcemia of malignancy complicating infantile fibrosarcoma.
Pediatr Blood Cancer
; 64(10)2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28371408
10.
Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.
Curr Treat Options Oncol
; 18(4): 24, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28391422
11.
Survivorship.
J Surg Oncol
; 111(5): 648-55, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25557722
12.
Soft Tissue Sarcomas in Adolescents and Young Adults.
J Clin Oncol
; 42(6): 675-685, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37967293
13.
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Clin Cancer Res
; 29(9): 1708-1718, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058010
14.
Pain and Analgesia in Children with Cancer after Hemipelvectomy: A Retrospective Analysis.
Children (Basel)
; 9(2)2022 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35204957
15.
Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Mol Cancer Ther
; 21(8): 1318-1325, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657346
16.
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma.
Mol Cancer Ther
; 21(6): 903-913, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35312779
17.
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium.
Mol Cancer Ther
; 20(3): 535-540, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33298592
18.
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
Int J Radiat Oncol Biol Phys
; 109(3): 718-725, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33516439
19.
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.
J Clin Med
; 10(7)2021 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33915882
20.
Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Cancer Med
; 10(3): 857-866, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33340280